ARTICLE | Clinical News
Amplimexon imexon regulatory update
January 16, 2006 8:00 AM UTC
EMEA granted Orphan Drug designation to Amplimexon to treat ovarian cancer. The small molecule cyanoaziridine already has U.S. Orphan Drug designation for this indication. ...